nach oben

Lung

Erschienen in:

26.10.2020 | PULMONARY DRUG DELIVERY

Exogenous Surfactant as a Pulmonary Delivery Vehicle for Budesonide In Vivo

verfasst von: Brandon Baer, Lynda McCaig, Cory Yamashita, Ruud Veldhuizen

Erschienen in: Lung | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Lung inflammation is associated with many respiratory conditions. Consequently, anti-inflammatory medications, like glucocorticoids, have become mainstay intrapulmonary therapeutics. However, their effectiveness for treating inflammation occurring in the alveolar regions of the lung is limited by suboptimal delivery. To improve the pulmonary distribution of glucocorticoids, such as budesonide to distal regions of the lung, exogenous surfactant has been proposed as an ideal delivery vehicle for such therapies. It was therefore hypothesized that fortifying an exogenous surfactant (BLES) with budesonide would enhance efficacy for treating pulmonary inflammation in vivo.

Methods

An intratracheal instillation of heat-killed bacteria was used to elicit an inflammatory response in the lungs of male and female rats. Thirty minutes after this initial instillation, either budesonide or BLES combined with budesonide was administered intratracheally. To evaluate the efficacy of surfactant delivery, various markers of inflammation were measured in the bronchoalveolar lavage and lung tissue.

Results

Although budesonide exhibited anti-inflammatory effects when administered alone, delivery with BLES enhanced those effects by lowering the lavage neutrophil counts and myeloperoxidase activity in lung tissue. Combining budesonide with BLES was also shown to reduce several other pro-inflammatory mediators. These results were shown across both sexes, with no observed sex differences.

Conclusion

Based on these findings, it was concluded that exogenous surfactant can enhance the delivery and efficacy of budesonide in vivo.

Newman SP (2017) Drug delivery to the lungs: challenges and opportunities. Ther Deliv 8:647–661CrossRefPubMed

Chandel A, Goyal AK, Ghosh G, Rath G (2019) Recent advances in aerosolised drug delivery. Biomed Pharmacother 112:108601. https://doi.org/10.1016/j.biopha.2019.108601CrossRefPubMed

Matthay MA, Ware LB, Zimmerman GA (2012) The acute respiratory distress syndrome. J Clin Invest 122:2731–2740. https://doi.org/10.1172/JCI60331CrossRefPubMedPubMedCentral

Heukels P, Moor CC, von der Thüsen JH et al (2019) Inflammation and immunity in IPF pathogenesis and treatment. Respir Med 147:79–91. https://doi.org/10.1016/j.rmed.2018.12.015CrossRefPubMed

Goerke J (1998) Pulmonary surfactant: functions and molecular composition. Biochim Biophys Acta Mol Basis Dis 1408:79–89. https://doi.org/10.1016/S0925-4439(98)00060-XCrossRef

Baer B, Souza LMP, Pimentel AS, Veldhuizen RAW (2019) New insights into exogenous surfactant as a carrier of pulmonary therapeutics. Biochem Pharmacol 164:64–73. https://doi.org/10.1016/j.bcp.2019.03.036CrossRefPubMed

Zuo YY, Veldhuizen R, Neumann W et al (2008) Current perspectives in pulmonary surfactant–inhibition, enhancement and evaluation. Biochim Biophys Acta 1778:1947–1977. https://doi.org/10.1016/j.bbamem.2008.03.021CrossRefPubMed

Halliday HL (2008) Surfactants: past, present and future. J Perinatol 28:S47–S56CrossRefPubMedPubMedCentral

Lopez E, Gascoin G, Flamant C et al (2013) Exogenous surfactant therapy in 2013: what is next? Who, when and how should we treat newborn infants in the future? BMC Pediatr 13:165. https://doi.org/10.1186/1471-2431-13-165CrossRefPubMedPubMedCentral

10.

Baer B, Veldhuizen EJA, Possmayer F et al (2018) The wet bridge transfer system: a novel tool to assess exogenous surfactant as a vehicle for intrapulmonary drug delivery. Discov Med 26:207–218PubMed

11.

Hidalgo A, Salomone F, Fresno N et al (2017) Efficient interfacially driven vehiculization of corticosteroids by pulmonary surfactant. Langmuir 33:7929–7939. https://doi.org/10.1021/acs.langmuir.7b01177CrossRefPubMed

12.

Mikolka P, Mokrá D, Kopincová J et al (2013) Budesonide added to modified porcine surfactant curosurf may additionally improve the lung functions in meconium aspiration syndrome. Physiol Res 62:191–200CrossRef

13.

Chen C-M, Chang C-H, Chao C-H et al (2019) Biophysical and chemical stability of surfactant/budesonide and the pulmonary distribution following intra-tracheal administration. Drug Deliv 26:604–611. https://doi.org/10.1080/10717544.2019.1618418CrossRefPubMedPubMedCentral

14.

Nimmo AJ, Carstairs JR, Patole SK et al (2002) Intratracheal administration of glucocorticoids using surfactant as a vehicle. Clin Exp Pharmacol Physiol 29:661–665. https://doi.org/10.1046/j.1440-1681.2002.03712.xCrossRefPubMed

15.

Khazaee R, McCaig LA, Yamashita C et al (2019) Maternal protein restriction during perinatal life affects lung mechanics and the surfactant system during early postnatal life in female rats. PLoS ONE 14:e0215611. https://doi.org/10.1371/journal.pone.0215611CrossRefPubMedPubMedCentral

16.

Banaschewski BJH, Baer B, Arsenault C et al (2017) The antibacterial and anti-inflammatory activity of chicken cathelicidin-2 combined with exogenous surfactant for the treatment of cystic fibrosis-associated pathogens. Sci Rep 7:15545. https://doi.org/10.1038/s41598-017-15558-4CrossRefPubMedPubMedCentral

17.

Milos S, Qua Hiansen J, Banaschewski B et al (2016) The effect of diet-induced serum hypercholesterolemia on the surfactant system and the development of lung injury. Biochem Biophys Rep 7:180–187. https://doi.org/10.1016/j.bbrep.2016.06.009CrossRefPubMedPubMedCentral

18.

Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917. https://doi.org/10.1139/o59-099CrossRefPubMed

19.

Duck-Chong CG (1979) A rapid sensitive method for determining phospholipid phosphorus involving digestion with magnesium nitrate. Lipids 14:492–497CrossRef

20.

Tyml K, Swarbreck S, Pape C et al (2017) Voluntary running exercise protects against sepsis-induced early inflammatory and pro-coagulant responses in aged mice. Crit Care. https://doi.org/10.1186/s13054-017-1783-1CrossRefPubMedPubMedCentral

21.

Wu YF, Su MW, Chiang BL et al (2017) A simple prediction tool for inhaled corticosteroid response in asthmatic children. BMC Pulm Med 17:176. https://doi.org/10.1186/s12890-017-0533-0CrossRefPubMedPubMedCentral

22.

Galant SP, Morphew T, Guijon O, Pham L (2014) The bronchodilator response as a predictor of inhaled corticosteroid responsiveness in asthmatic children with normal baseline spirometry. Pediatr Pulmonol 49:1162–1169. https://doi.org/10.1002/ppul.22957CrossRefPubMed

23.

Dijkstra A, Vonk JM, Jongepier H et al (2006) Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax 61:105–110. https://doi.org/10.1136/thx.2004.039271CrossRefPubMed

24.

Gerald JK, Gerald LB, Vasquez MM et al (2015) Markers of differential response to inhaled corticosteroid treatment among children with mild persistent asthma. J Allergy Clin Immunol Pract 3:540-546.e3. https://doi.org/10.1016/j.jaip.2015.01.023CrossRefPubMedPubMedCentral

25.

Tantisira KG, Colvin R, Tonascia J et al (2008) Airway responsiveness in mild to moderate childhood asthma: ssex influences on the natural history. Am J Respir Crit Care Med 178:325–331. https://doi.org/10.1164/rccm.200708-1174OCCrossRefPubMedPubMedCentral

26.

Casimir GJ, Lefèvre N, Corazza F, Duchateau J (2013) Sex and inflammation in respiratory diseases: a clinical viewpoint. Biol Sex Differ 4:16CrossRefPubMedPubMedCentral

27.

Bereshchenko O, Bruscoli S, Riccardi C (2018) Glucocorticoids, sex hormones, and immunity. Front Immunol 9:1332CrossRefPubMedPubMedCentral

28.

Rebetz J, Semple JW, Kapur R (2018) The pathogenic involvement of neutrophils in acute respiratory distress syndrome and transfusion-related acute lung injury. Transfus Med Hemother 45:290–298CrossRefPubMedPubMedCentral

29.

Venkataraman R, Kamaluddeen M, Hasan SU et al (2017) Intratracheal administration of budesonide-surfactant in prevention of bronchopulmonary dysplasia in very low birth weight infants: a systematic review and meta-analysis. Pediatr Pulmonol 52:968–975. https://doi.org/10.1002/ppul.23680CrossRefPubMed

30.

Michael Z, Spyropoulos F, Ghanta S, Christou H (2018) Bronchopulmonary dysplasia: an update of current pharmacologic therapies and new approaches. Clin Med Insights Pediatr 12:117955651881732. https://doi.org/10.1177/1179556518817322CrossRef

31.

Yeh TF, Chen CM, Wu SY et al (2016) Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. Am J Respir Crit Care Med 193:86–95. https://doi.org/10.1164/rccm.201505-0861OCCrossRefPubMed

32.

Boel L, Banerjee S, Chakraborty M (2018) Postnatal steroids in extreme preterm infants: intra-tracheal instillation using surfactant as a vehicle. Paediatr Respir Rev 25:78–84PubMed

33.

Kuo HT, Lin HC, Tsai CH et al (2010) A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants. J Pediatr 156:537–541. https://doi.org/10.1016/j.jpeds.2009.10.049CrossRefPubMed

34.

Bosma KJ, Taneja R, Lewis JF (2010) Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome: current and experimental approaches. Drugs 70:1255–1282CrossRefPubMedPubMedCentral

35.

Ferguson ND, Fan E, Camporota L et al (2012) The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med 38:1573–1582. https://doi.org/10.1007/s00134-012-2682-1CrossRefPubMed

36.

Rozance PJ, Seedorf GJ, Brown A et al (2011) Intrauterine growth restriction decreases pulmonary alveolar and vessel growth and causes pulmonary artery endothelial cell dysfunction in vitro in fetal sheep. Am J Physiol Lung Cell Mol Physiol 301:L860. https://doi.org/10.1152/ajplung.00197.2011CrossRefPubMedPubMedCentral

37.

Wan Y, Shang J, Graham R et al (2020) Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. https://doi.org/10.1128/jvi.00127-20CrossRefPubMedPubMedCentral

38.

Williams AE, Chambers RC (2014) The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol 306:L217CrossRefPubMed

39.

Scott B, Kubes P, Snyder J (2018) Death to the neutrophil! A resolution for acute respiratory distress syndrome? Eur Respir J 52:1801274. https://doi.org/10.1183/13993003.01274-2018CrossRefPubMed

40.

Horby P, Lim WS, Emberson J et al (2020) Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. https://doi.org/10.1101/2020.06.22.20137273CrossRef

41.

Han S, Mallampalli RK (2015) The acute respiratory distress syndrome: from mechanism to translation. J Immunol 194:855–860. https://doi.org/10.4049/jimmunol.1402513CrossRefPubMed

42.

Boyle AJ, Sweeney RM, McAuley DF (2013) Pharmacological treatments in ARDS; a state-of-the-art update. BMC Med 11:166CrossRefPubMedPubMedCentral

43.

Coorens M, Banaschewski BJH, Baer BJ et al (2017) Killing of P. aeruginosa by chicken cathelicidin-2 is immunogenically silent, preventing lung inflammation in vivo. Infect Immun IAI. https://doi.org/10.1128/IAI.00546-17CrossRef

44.

Cross LJM, Matthay MA (2011) Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury. Crit Care Clin 27:355–377CrossRefPubMedPubMedCentral

45.

Park WY, Goodman RB, Steinberg KP et al (2001) Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 164:1896–1903. https://doi.org/10.1164/ajrccm.164.10.2104013CrossRefPubMed

46.

Haitsma JJ, Lachmann U, Lachmann B (2001) Exogenous surfactant as a drug delivery agent. Adv Drug Deliv Rev 47:197–207. https://doi.org/10.1016/S0169-409X(01)00106-5CrossRefPubMed

Titel: Exogenous Surfactant as a Pulmonary Delivery Vehicle for Budesonide In Vivo
verfasst von: Brandon Baer
Lynda McCaig
Cory Yamashita
Ruud Veldhuizen
Publikationsdatum: 26.10.2020
Verlag: Springer US
Erschienen in: Lung / Ausgabe 6/2020
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-020-00399-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Follow-Up Functional Class and 6-Minute Walk Distance Identify Long-Term Survival in Pulmonary Arterial Hypertension

Benefits and Risks of Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease Classified by Blood Eosinophil Counts

Is There (Will There Be) a Post-COVID-19 Chronic Cough?

ACE2: The Major Cell Entry Receptor for SARS-CoV-2

A Multidisciplinary Lung Cancer Program: Does It Reduce Delay Between Diagnosis and Treatment?